Results 11 to 20 of about 43,043 (156)

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia [PDF]

New England Journal of Medicine, 2017
BACKGROUND Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B ...
Arslan, O, Bassan, R, Bergeron, J, Brueggemann, M, Demirkan, F, Dombret, H, Fielding, AK, Fleishman, A, Foa, R, Goekbuget, N, Holland, C, Horst, H-A, Kantarjian, H, Klapper, W, Lech-Maranda, E, Nagorsen, D, Rambaldi, A, Ribera, J-M, Sanz, MA, Schuh, AC, Stein, A, Thomas, X, Topp, MS, Wei, A, Wood, BL, Zimmerman, Z   +25 more
core   +5 more sources

Incidence of Hodgkin and Non-Hodgkin Lymphomas: Comparison of the Military and General Population. [PDF]

Cancer Med
ABSTRACT Background Lymphoma risk varies by demographics, environmental/occupational exposures, and medical care between active‐duty service members (ADSM) and the general US population (GUSP). This study compared age‐adjusted incidence rates and trends of Hodgkin lymphoma (HL) and non‐Hodgkin lymphoma (NHL) between these groups.
Robins KR, Bytnar JA, DeStefano CB, Shriver CD, Zhu K.   +4 more
europepmc   +2 more sources

Benign TdT-positive cells in pediatric and adult lymph nodes: a potential diagnostic pitfall [PDF]

, 2018
Benign TdT-positive cells have been documented in a variety of non-hematopoietic tissues. Scant data are however available on their presence in non-neoplastic lymph nodes.
AGOSTINELLI, CLAUDIO, Bertuzzi, Clara, BRIGNOLA, STEFANO, Pillon, Marta, Pizzi, Marco, Righi, Simona, Rugge, Massimo, Sabattini, Elena, Semenzato, Gianpietro   +8 more
core   +1 more source

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco, Maffini, Enrico, Saraceni, Francesco   +2 more
core   +1 more source

ABL oncogene amplification with p16^INK4a gene deletion in precursor T‐cell acute lymphoblastic leukemia/lymphoma: Report of the first case [PDF]

American Journal of Hematology, 2004
AbstractGene amplification is a relatively rare event in hematologic malignancies. The ABL gene on chromosome band 9q34 is a proto‐oncogene and is the well‐known translocation partner of the BCR gene on 22q11 giving rise to t(9;22)(q34;q11), which is the hallmark of chronic myeloid leukemia and is the most common chromosomal abnormality in adult acute ...
Hee-Jin, Kim, Hee-Yeon, Woo, Hong-Hoe, Koo, Eun-Young, Tak, Sun-Hee, Kim   +4 more
openaire   +2 more sources

MicroRNAs in B cell development and malignancy [PDF]

, 2012
MicroRNAs are small RNA molecules that regulate gene expression and play critical roles in B cell development and malignancy. miRNA expression is important globally, as B cell specific knockouts of Dicer show profound defects in B cell development; and ...
Fernando, Thilini R., Rao, Dinesh S., Rodriguez-Malave, Norma I.   +2 more
core   +4 more sources

Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia. [PDF]

, 2016
High hyperdiploidy (HD), the most common cytogenetic subtype of B-cell acute lymphoblastic leukemia (B-ALL), is largely curable but significant treatment-related morbidity warrants investigating the biology and identifying novel drug targets.
de Smith, Adam J, Endicott, Alyson A, Francis, Stephen S, Hansen, Helen M, Metayer, Catherine, Ojha, Juhi, Sanders, Erica, Smirnov, Ivan, Termuhlen, Amanda M, Walsh, Kyle M, Wiemels, Joseph L   +10 more
core   +1 more source

Multi-Institution Review of Adult Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma (ETP-ALL)

Blood, 2015
Abstract Background: The Early T-cell precursor (ETP) variant of acute lymphoblastic lymphoma/leukemia (ALL) is a recognized high risk variant, recognized by the absence of CD1a, with aberrant myeloid antigen expression (CD13, CD33, CD117, and CD34), and frequent absence of CD4 or CD8. Treatment intensification may improve
Bijal D. Shah, Uma Borate, Vamsi K Kota, Ling Zhang, Deniz Peker, Amanda Redden Hathaway, Julio C Chavez   +6 more
openaire   +1 more source

Adipocytes cause leukemia cell resistance to daunorubicin via oxidative stress response. [PDF]

, 2016
Adipocytes promote cancer progression and impair treatment, and have been shown to protect acute lymphoblastic leukemia (ALL) cells from chemotherapies. Here we investigate whether this protection is mediated by changes in oxidative stress.
Behan, James W, Heisterkamp, Nora, Ji, Lingyun, Mittelman, Steven D, Parmentier, Jean-Hugues, Sheng, Xia, Tucci, Jonathan   +6 more
core   +1 more source

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia [PDF]

, 2015
Several chemo-resistance mechanisms including the Bcl-2 protein family overexpression and constitutive activation of the PI3K/Akt/mTOR signaling have been documented in acute lymphoblastic leukemia (ALL), encouraging targeted approaches to circumvent ...
ALLEGRETTI, MATTEO, Bergamo, P, FOA, Roberto, Iacovelli, S, LICCHETTA, ROBERTO, Martelli, Am, Mccubrey, Ja, Milella, M, MIRABILII, SIMONE, RICCIARDI, Maria Rosaria, Rinaldo, C, TAFURI, Agostino, Zeuner, A   +12 more
core   +1 more source